Table 2.
Effect of intervention at 3 months follow-up
| Usual care |
Home |
Between groups comparison | 95% CI | |||
|---|---|---|---|---|---|---|
| Δ 0–3 months | 95% CI | Δ 0–3 months | 95% CI | |||
| Exercise capacity | ||||||
| 6MWT, m | 10.1 | −23.6, 43.9 | 36.3 | −0.9, 73.6 | 26.2 | −24.1 to 76.5 |
| STS | 0.9 | −0.8, 2.6 | 1.0 | −0.8, 2.8 | 0.1 | −2.3 to 2.6 |
| Clinical status | ||||||
| Systolic blood pressure, mm Hg | 2.0 | −8.4, 12.4 | −12.9 | −24.2, −1.6* | −14.9 | −30.2 to 0.5 |
| Diastolic blood pressure, mm Hg | 4.1 | −2.2, 10.5 | −1.5 | −8.4, 5.4 | −5.7 | −15.0 to 3.7 |
| BMI, kg/m2 | 0.1 | −1.3, 1.5 | −0.5 | −2.1, 1.1 | −0.6 | −2.7 to 1.5 |
| Waist–hip ratio | −0.01 | −0.03, 0.01 | −0.01 | −0.03, 0.01 | 0 | −0.03 to 0.03 |
| Laboratory values | ||||||
| Total cholesterol, mmol/l | −0.2 | −0.6, 0.2 | −0.1 | −0.5, 0.4 | 0.1 | −0.5, 0.7 |
| HDL cholesterol, mmol/l | 0.1 | −0.01, 0.2 | 0.1 | −0.1, 0.2 | −0.04 | −0.2, 0.1 |
| LDL cholesterol, mmol/l | −0.2 | −0.5, 0.1 | −0.1 | −0.5, 0.3 | 0.1 | −0.4 to 0.6 |
| Cholesterol/HDL ratio | −0.4 | −0.7, 0 | −0.3 | −0.7, 0.1 | 0.1 | −0.5 to 0.7 |
| HRQoL, anxiety and depression | ||||||
| HADS anxiety score | −0.9 | −2.3, 0.5 | −1.2 | −2.7, 0.6 | −0.3 | −2.4 to 1.9 |
| HADS depression score | −1.1 | −2.6, 0.4 | −1.0 | −2.7, 0.6 | 0.1 | −2.2 to 2.3 |
| SF-12 PCS | 2.7 | −1.4, 6.8 | −0.4 | 5.1, 4.3 | −3.1 | −9.4 to 3.1 |
| SF-12 MCS | 3.5 | −0.9, 7.9 | 2.4 | −2.6, 7.5 | −1.0 | −7.7 to 5.6 |
All data are adjusted for age and gender.
*p<0.05.
BMI, body mass index; HADS, hospital anxiety and depression score; HDL, high density lipoprotein; HRQoL, health-related quality of lifeLDL, low density lipoprotein; MCS, mental component summary scale of SF-12; PCS, physical component summary scale of SF-12; STS, sit to stand test; 6MWT, 6 min walk test.